Download National Cancer Drugs Fund Application Form – Cetuximab for

National Cancer Drugs Fund Application Form –
Cetuximab
for Metastatic Colorectal Cancer
(1st Line in Combination with Irinotecan Based Chemotherapy)
Instructions to Consultants: Please fill in each section of the form electronically and save the
document with your own file name. [If you continue typing the boxes will enlarge to contain the text].
Please send electronically to ______________________. Please also send copies to your Trust’s link
accountant / corporate contracting team.
Security of Patient Identifiable Information: The patient will be identified by their NHS number only.
Please do not include any other patient identifiers for confidentiality reasons. All communication must be
sent to the Cancer Drugs Fund Office via secure e mail accounts: that is from an nhs.net account to the
____________ account.
Receipt of Application: The sender of the application will receive an acknowledgement, together with
details of the unique Cancer Drugs Fund reference.
Cancer Drugs Fund Policy: To check the status of a particular therapy please check the Cancer Drugs
Fund Policy at _________________
Applications will be subject to Clinical Audit arrangements.
Approved Treatment Required for Cetuximab for Metastatic Colorectal Cancer – 1st
Line in Combination with Irinotecan Based Chemotherapy
TICK
All 7 conditions must be met
1. Application made by and first cycle of systemic anti-cancer therapy to be
prescribed by a consultant specialist specifically trained and accredited in the
use of systemic anti-cancer therapy
2. Metastatic colorectal cancer
3. 1st line indication
4. Patients with wild-type KRAS
5. Given in combination with Irinotecan-based combination chemotherapy
6. Not eligible for NICE TA176 approved indications (including patients who have
not progressed despite receiving the NICE approved 16 weeks treatment)
7. No previous treatment with Cetuximab
NOTE: Cetuximab is not approved for use with oxaliplatin-based combination or single
agent fluoropyrimidine chemotherapy
Note: No treatment breaks of more than 4 weeks beyond the expected cycle length are
allowed (to allow any toxicity of current therapy to settle or in the case of intercurrent comorbidities)
Note: If excessive toxicity with irinotecan, cetuximab can be continued with a
fluoropyrimidine alone until disease progression only.
Consultant Approval (email authority)
National Cancer Drugs Fund – Application Form 1 April 2013
Cetuximab for Metastatic Colorectal Cancer
1st Line in Combination with Irinotecan Based Chemotherapy
Page 1
Patient Consent Obtained (date of letter – copy to be retained on patient file)
National Cancer Drugs Fund – Application Form 1 April 2013
Cetuximab for Metastatic Colorectal Cancer
1st Line in Combination with Irinotecan Based Chemotherapy
Page 2
Proposed Start Date for Therapy (add clinic date)*:
Consultant details*
(including signature or
email confirmation)
Name:
Hospital:
Address:
Post Code:
Telephone:
Nhs.net
Trust Pharmacist details of the Trust where
the patient will be
treated*
Mandatory - NHS No*:
Mandatory – Patients
date of birth*
Optional – Hospital No.
Clinical Commissioning
Group*
Patient’s GP*
(name, address,
telephone)
Name:
Hospital:
Address:
Post Code:
Telephone:
Nhs.net
NHS No:
DOB:
Hospital No:
CCG Name:
Name:
Address:
Post Code:
ICD-10 Code (please tick
the relevant box)*
C18 - Malignant neoplasm of colon
C19 - Malignant neoplasm of rectosigmoid junction
C20 - Malignant neoplasm of rectum
HRG Code
Completion of items marked with * is mandatory. Failure to complete these items may
mean that payment is not made.
National Cancer Drugs Fund – Application Form 1 April 2013
Cetuximab for Metastatic Colorectal Cancer
1st Line in Combination with Irinotecan Based Chemotherapy
Page 3